drugset / Trial / NCT01402180
Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy
Phase 2/3
Unknown
128 enrolled
Fudan University
RenJi Hospital · collabShanghai Chest Hospital · collabShanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collabShanghai Pulmonary Hospital, Shanghai, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized phase II tials to study whether it's benefit of adding Nimotuzumab to chemoradiation for patients with esophageal squamous cell carcinoma after radical esophagectomy who suffer with locoregional lymph nodes recurrence.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | — | — |